

## **Supplementary Information for**

# **Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy.**

Shirin Lak<sup>1</sup>, Valérie Janelle<sup>1</sup>, Anissa Djedid<sup>2</sup>, Gabrielle Boudreau<sup>1</sup>, Ann Brasey<sup>1,3</sup>, Véronique Lisi<sup>2</sup>, Cédric Carli<sup>1</sup>, Lambert Busque<sup>1,3,4,5</sup>, Vincent-Philippe Lavallée<sup>2,6,7</sup>, Jean-Sébastien Delisle<sup>1,4,5</sup>

<sup>1</sup> Centre de recherche de l'Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada

<sup>2</sup> Centre de recherche du CHU Sainte-Justine, Montréal, Qc, Canada

<sup>3</sup> Biomarker Unit, Centre C3i, Montréal, Qc, Canada

<sup>4</sup> Department of Medicine, Université de Montréal, Montréal, Qc, Canada

<sup>5</sup> Hematology-Oncology and Cell therapy Division, Hôpital Maisonneuve-Rosemont, Montréal, Qc, Canada

<sup>6</sup> Department of Pediatrics, Université de Montréal, Montréal, Qc, Canada

<sup>7</sup> Hematology-Oncology Division, CHU Sainte-Justine

\* Jean-Sébastien Delisle.

**Email:** [js.delisle@umontreal.ca](mailto:js.delisle@umontreal.ca)

**This PDF file includes:**

Tables S1 to S3

Figures S1 to S3

**Supplementary Table S1:** Single cell filtering results. Initial number of barcodes represents the output from CellRanger v3.0.2 while the number of cells after filtering corresponds to the cells kept for downstream analysis.

<b>Sample</b>	<b>Initial number of barcodes</b>	<b>Number of cells after filtering</b>
CTRL1	20182	12753
CTRL2	8550	1950
CTRL3	27019	9109
DB1	19724	10101
DB2	11107	2665
DB3	30813	8981

**Supplementary Table S2:** Gene list used for analysis.

<b>TCA cycle</b>	<b>G2-M</b>	<b>Pentose Phosphate Pathway</b>		<b>Lipid mediators</b>		<b>Glycogen Metabolism</b>	<b>Glycogen Metabolism</b>	<b>Glucose Deprivation</b>
ACLY	AURKA	G6PD	ADIPOQ	GH1	FASN	GBE1	GBE1	NRN1
ACO1	BIRC5	G6PDH	TNFRSF9	HGF	IRS2	GYS1	GYS1	FAM129A
ACO2	BUB1	PGLS	AgRP	ICAM1	KLF15	GYS2	GYS2	IL23A
CS	BUB1B	PRPS1	ANGPT1	IGFBP1	PPARG	UGP2	UGP2	SPRY1
DLAT	CCNA2	PRPS1L1	ANGPT2	IGFBP2	PPARGC1A	AGL	AGL	GADD45B
DLD	CCNB1	PRPS2	ANGPTL3	IGFBP3	RETN	PGM1	PGM1	HSPA1A
DLST	CCNB2	RBKS	ANGPTL4	IGFBP4	SIRT3	PGM2	PGM2	HSPA1B
FH	CCNF	RPE	ANGPTL6	IGFBP6	SLC2A4	PGM3	PGM3	GPNMB
IDH1	CDC20	RPIA	TNFSF13B	IGFBP7	SREBF1	PYGL	PYGL	HAVCR2
IDH2	CDC25B	TALDO1	BMP4	IL1b	ACACB	PYGM	PYGM	SOAT2
IDH3A	CDC25C	TKT	CTSD	IL6	AXIN1	GSK3A	GSK3A	ADAMTS6
IDH3B	CDK1		CTSS	IL10	CCND1	GSK3B	GSK3B	
IDH3G	CDKN2D		CCL2	IL11	CDK4	PHKA1	PHKA1	
MDH1	CENPA		CCL5	INS	CEBPB	PHKB	PHKB	
MDH1B	CENPF		RARRES2	LEP	CEBPD	PHKG1	PHKG1	
MDH2	CKS2		CFD	LIF	DKK1	PHKG2	PHKG2	
OGDH	KIF20A		CRP	LCN2	E2F1			
PC	PLK1		CXCL8	CSF1	FABP4			
PCK1	RACGAP1		DPP4	MIF	FASN			
PCK2	TOP2A		ESM1	MPO				
PDHA1			S100A12	GHRL				
PDHB			AHSG	GHSR				
SDHA			FGF1	LIPE				
SDHB			FGF2	LPL				
SDHD			FGF21	AGT				
SUCLA2			FGF23	CEBPA				
SUCLG1			LGALS3	CFD				
SUCLG2			GCG	FABP4				

**Supplementary Table S2:** Gene list used for analysis (continued).

<b>Glycolysis</b>	<b>Hypoxia-HIF regulated</b>		<b>Type II Interferon Response</b>	<b>Type I Interferon Response</b>	<b>Anti-inflammatory</b>	<b>Pro-inflammatory</b>	<b>Anergy</b>	<b>T- Cell Terminal Differentiation</b>
ALDOA	LAMB1	IL10RA	IFNG	IRF1	TIGIT	IL1A	EGR3	TIGIT
ALDOB	ALDOA	IL15RA	CXCL9	IFIH1	IDO1	IL1B	NR4A3	PDCD1
ALDOC	ADM	ITGA6	CXCL10	IFITM3	LGALS3	TNF	EGR1	CD274
BPGM	BCL2	ITK	STAT1	DDX58	PDCD1	IFNG	NR4A2	CTLA4
ENO1	BCL2L1	JUND	CD274	IFI44L	FOXP3	TBX21	EGR2	LAG3
ENO2	FOS	IGHG4	CDKN1A	IFI6	ENTPD1	CCL3	TNFSF11	HAVCR2
GALM	JUN	MAP3K5	MYC	IFITM2	CD274	CCL4	IRF4	CD244
GCK	SRC	MAP2K1	SMAD7	NAMPT	CSF2	PRF1	GCH1	CD160
GPI	CREBBP	MAP2K2	IRF1	OASL	CTLA4	GZMA	GADD45B	
HK2	CCR6	MIF	HLA-F	RTP4	CXCL12	GZMB	NFATC1	
HK3	CEBPB	NFATC1	HLA-G	TREX1	CXCL5	GZMK	JARID2	
PFKL	ENO1	NFKB2	HLA-A	ADAR	CXCL8	GZMH	SLC29A3	
PGAM2	FAS	NFKBIE	HLA-E	TENT5C	MIF	CD8A	HLF	
PGK1	FASLG	TP53	HLA-C	LY6E	PTGS2	FASLG	ZFP36L1	
PGK2	FKBP4	TGM6	HLA-B	MCOLN2	VEGFA	CCL2	RNF19A	
PGM1	GAPDH	TNF	HLA-DRA	APOBEC3G		CCL20	ADORA2B	
PGM2	SLC2A1	TNFRSF1B	HLA-DRB5	IL15		IL2	NOCT	
PGM3	SLC2A3	TRADD	HLA-DRB1	ISG15		IL6	DUSP6	
PKLR	CSF2	TNFSF10	HLA-DQA1	MX1		IL12a	NDRG1	
TPI1	IFNG	TRAP1	HLA-DQB1	TLR3		IL17a	ADORA2A	
	IFNB1	VEGFA	HLA-DQB1-AS1			IL23a	HSPA1A	
	IL13		HLA-DQA2			PTGS2	PFKP	
	IL1R1		HLA-DQB2			TLR4	FYN	
	IL2RA		HLA-DOB			TNF	CTSE	
	IL4		HLA-DMB				ZNF629	
	IL5		HLA-DMA				F2R	
	IL6R		HLA-DOA				RNF128	
	CXCL8		HLA-DPA1				LAG3	
			HLA-DPB1				RGS16	
			HLA-DPA1				E2F1	
							E2F2	


**Supplementary Table S2:** Gene list used for analysis (continued).

<b>T-Cell Proliferation</b>	<b>CD8 T-Cell Activation</b>	<b>Cytolytics effector pathway</b>	<b>Exhaustion</b>
UBE2T	CD69	EOMES	TOX
CENPU	CCR7	TBX21	TOX2
CHEK1	CD27	GZMB	EOMES
AURKA	BTLA	PRF1	TBX21
CAPG	CD40LG	FASLG	NR4A2
PCLAF	IL2RA	GZMH	PRDM1
BUB1B	CD3E	GZMA	PDCD1
CCNB2	CD47		HAVCR2
DLC1	EOMES		CD244
CDK1	GNLY		CD160
CCNA2	GZMA		LAG3
SERPINB2	GZMB		CD38
PCNA	PRF1		ENTPD1
TOP2A	IFNG		CD101
STAT5A	CD8A		IFNG
IL2	CD8B		TNF
	FASLG		IL2
	LAMP1		CTLA4
	LAG3		
	CTLA4		
	HLA-DRA		
	TNFRSF4		
	ICOS		
	TNFRSF9		
	TNFRSF18		

**Supplementary Table S3:** TCR alpha/beta chain sequences of the most abundant clonotypes across donors and conditions.


Clonotype ID	nt_TRA	nt_TRB	aa_TRA	aa_TRB	Donor
clonotype1	TGTGCTGCCCTCATGGATAGCAACTATCAGT TAATCTGG	TGCGCCAGCAGTGATGACGGGATGAACACT GAAGCTTTCTTT	CAALMDSNYQLIW	CASSDDGMNTEAFF	1 and 2
clonotype2	TGTGCTGTGCTCATGGATAGCAACTATCAGT TAATCTGG	TGCGCCAGCAGTGGGGACGGTATGAACACT GAAGCTTTCTTT	CAVLMSNYQLIW	CASSGDMNTEAFF	3
clonotype3	TGTGCAATGAGCGCGGAGGAGGACATGCGC TTT	TGTGCCAGCAGCTCCCGGCTAGCGGGGATC CAAACGAGCTCCTACAATGAGCAGTTCTTC	CAMSAEEDMRF	CASSRSLAGIQTSSYNEQFF	1 and 2
clonotype4	TGTGCAATGAGCGCGGAATCAAATCCGGGT ATGCACTCAACTTC	TGTGCCAGCAGCTTAGGGGGTTATGAGCAG TTCTTC	CAMSAESNSGYALNF	CASSLGGYEQFF	3
clonotype5	TGTGCAAGGGCCGGGGCTGGGAGTTACCAA CTCACTTC	TGCGCCAGCAGCTTGAGGGACAGCGGAGC TCCTACGAGCAGTACTTC	CAGAGAGSYQLTF	CASSLEGQASSYEQYF	2
clonotype6	TGTGCTGTGACTAACTTTGAAATGAGAAATT AACCTTT	TGCGCCAGCAGCCAACACTACAGGGATACGAG CAGTACTTC	CAVTNFGNEKLTf	CASSQLQGYEQYF	2
clonotype7	TGTGCAATGAGAGAGCCTCTCACGGGAGGA GGAACAAACTCACCTTT	TGTGCCAGCAGTGGACTAGCGATCTCCTACG AGCAGTACTTC	CAMREPLTGGGNKLTf	CASSGLAISYEQYF	1

nt: nucleotide; aa: amino acid; TRA: TCR alpha chain; TRB: TCR beta chain.




**Supplementary Figure S1. Validation of the DDB strategy using isotype control antibodies.**

(A) Cell expansion relative to input at the beginning of the culture ( $15 \times 10^6$ ) in function of time and culture condition; no antibodies (ctrl), isotypes (ISO) according to the Delayed double blockade (DDB) scheme or DDB. Absolute count (B) and percentage (C) of HLA-A0201-LMP2<sub>426-434</sub> (LMP2) multimer positive T cells in the same conditions and at the same time-points. 3 different donors, significant p-values are indicated, error bars indicate SEM.



**Supplementary Figure S2. Correlation between clonotype determination using single-cell RNA sequencing (scRNA-seq) and bulk CDR3 beta-chain TCR sequencing.** Comparison of clonotype repertoire among sorted HLA-A0201-LMP2<sub>426-434</sub> multimer positive T cells at day 28 from the control condition (CTRL) and delayed double blockade (DDB) condition according to scRNA-seq or bulk CDR3 sequencing (bulk TCR-Seq) for each donor. The bulk TCR-Seq from the CTRL condition in Donor 3 was not considered due to poor RNA quality.





**Supplementary Figure S3. Limited overlap between HLA-A0201-LMP2<sub>426-434</sub> multimer positive and negative T cells.** Bulk CDR3 beta-chain TCR sequencing data from sorted multimer positive (+) and negative (-) fractions from all donors in both experimental condition (control - CTRL and delayed double blockade – DDB) at the day 21 and 28 time points showing limited clonotype overlap. Clonotypes present in both fractions (identified by beta-chain CDR3 sequences) are represented with none being abundant (>10%) in both fraction simultaneously. Due to poor RNA quality, the multimer-positive fraction of the control condition in Donor 3 could not be analyzed.